You are here

Bendamustine Receives FDA Approval

FRAZER, Pa.--(BUSINESS WIRE)--March 20, 2008--Cephalon, Inc. (Nasdaq:CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA will be available to physicians and patients as a CLL treatment in the United States in April 2008.

"TREANDA is an important new treatment for patients with chronic lymphocytic leukemia, and this first-cycle approval by FDA represents a significant milestone in the growth of our oncology business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology is poised to deliver therapies that target both hematologic cancers and solid tumors for patients in need of new options."

Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C., stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years because of treatments that control the disease over the long-term. TREANDA is an effective new option that offers a delay in disease progression, an important goal for patients with chronic lymphocytic leukemia."

In a randomized, international, multicenter, open-label pivotal study of 301 treatment-naive patients with CLL, those who received TREANDA had better clinical outcomes compared to patients treated with chlorambucil, an FDA-approved chemotherapy for patients with CLL. Specifically, TREANDA patients had a significantly higher overall response (59 percent of patients responded to TREANDA and 26 percent of patients responded to chlorambucil; p Importantly, TREANDA patients also had a significantly longer progression-free survival (18 months vs. 6 months; Hazard Ratio = 0.27; p TREANDA has been granted orphan drug status by the FDA for the treatment of CLL. The orphan drug designation will provide marketing exclusivity in this indication until March 2015.

About TREANDA
TREANDA has a unique chemical structure with two primary components, an alkylating group and a benzimidazole component. Preclinical data suggest that TREANDA can lead to cell death via several pathways. TREANDA damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death (non-apoptotic) pathway known as mitotic catastrophe (a disruption of normal cell division). The exact mechanism of action of TREANDA remains unknown.

In December 2007, Cephalon submitted an NDA requesting approval of TREANDA for the treatment of patients with indolent (slow-growing) non-Hodgkin's lymphoma who have progressed during or following treatment with rituximab or a rituximab-containing regimen and anticipates a review decision by October 31, 2008. The protocol for the TREANDA NHL pivotal trial received special protocol assessment (SPA) approval from the FDA in February 2006. The SPA process allows for FDA evaluation and acceptance of a clinical trial protocol, including trial size, clinical endpoints and/or data analysis.

Source: Cephalon, Inc.

Recent Headlines

Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs